Jaguar Health’s (JAGX) Napo Pharmaceuticals and Napo Therapeutics announced that the first patient has been dosed in the independent investigator-initiated POC trial of crofelemer, Jaguar’s novel plant-based anti-diarrheal prescription drug, for the rare disease indication of MVID in pediatric patients. POC data generated from this study potentially in the first half of 2025 could lead to reimbursed early patient access to crofelemer for this indication in certain European countries.The trial will also include pediatric patients with SBS-IF. It is being conducted by Dr. Mohamad Miqdady, a leader in pediatric gastroenterology who is the Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City, a flagship tertiary hospital in the UAE and the largest teaching medical center in Abu Dhabi. The trial is taking place at SKMC. Autosomal recessive disorders and congenital anomalies such as MVID are more prevalent in the Middle East and North Africa region.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health announces import of coca leaf by Magdalena Biosciences JV
- Jaguar Health’s Napo initiates Phase 2 study to evaluate crofelemer for MVID
- Jaguar Health participates in a conference call with Ladenburg Thalmann
- Jaguar Health granted Orphan Drug designation for crofelemer for diarrhea
- Biotech Alert: Searches spiking for these stocks today